14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ATRA ranks #16854 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Atara Biotherapeutics Stock Forecast NASDAQ:ATRA

$15.12 (-4.06%)

Volume: 797k

Closed: Oct 15, 2021

Hollow Logo Score: -4.428

Atara Biotherapeutics Stock Forecast

$15.12 (-4.06%)

Volume: 797k

Closed: Oct 15, 2021

Score Hollow Logo -4.428

Atara Biotherapeutics Stock News NASDAQ:ATRA

Pierre Fabre to Commercialize Tab-cel for Epstein-Barr Virus (EBV)-Positive Cancers in Europe, Middle East, Africa, and Other Select Emerging Markets Atara to Receive Upfront Payment of USD 45 Mil Read more
SOUTH SAN FRANCISCO, Calif. & CASTRES, France--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will receive Read more

Atara: EMA Grants Accelerated Assessment To Tab-cel - Quick Facts

01:12pm, Monday, 27'th Sep 2021 Business Insider Markets
(RTTNews) - Atara Biotherapeutics, Inc. (ATRA) said the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted accelerated assessment to the company''s lead product candidate, tabelecleucel, for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease. Atara said MAA for Read more
Designation recognizes therapeutic innovation and potential to address significant unmet patient need Atara on track to submit MAA in November 2021 Phase 3 ALLELE study analysis supporting tab-cel Read more

Atara Biotherapeutics: One More Time

09:26am, Monday, 20'th Sep 2021 Seeking Alpha
Read more
Immunotherapy is an emerging concept that involves the passive transfer of immune cells, which may or may not be modified / genetically altered to express a desired set of traits and / or features. Characterized by key features such as Read more
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a panel discussion titled, Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy, at the Citi 16th Read more
Related Stocks: VRTX , FATE , RCUS , ATRA , ZNTL , TCRR , HZNP , ACCD , JAZZ , BMRN , REGN , ABBV , RVMD , RCKT , TGTX , Read more
H.C. Wainwright Stick to Their Buy Rating for Atara Biotherapeutics Read more
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week. BeyondSpring Inc. (NASDAQ: BYSI ) was among the biggest biopharma gainers of the week, with the stock reacting to a positive late-stage readout for its lung cancer treatment combo. The stock ended the week with a gain of about 128%. Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA ), however, was not as fortunate, as the stock lost about one-fifth of its market cap following mixed results from a pivotal trial of its RNAi therapeutic candidate nedosiran in primary hyperoxaluria 1. The market reacted negatively to earnings from vaccine companies Moderna, Inc. (NASDAQ: MRNA ) and Novavax, Inc. (NASDAQ: NVAX ). Moderna''s results, although outstanding, elicited negative reaction, while a lack of update about U.S. approval of Novavax'' vaccine sent its shares tumbling on Friday. Read more

Atara Biotherapeutics Inc hosts conference call for investors

12:54pm, Saturday, 07'th Aug 2021 Business Insider Markets
The company, Atara Biotherapeutics Inc, is set to host investors and clients on a conference call on 8/9/2021 2:10:38 PM. The call comes after the company''s earnings, which are set to be announced on 8/9/2021.Investors, or members of the public who wish to dial in, can join the call by visiting Read more
CAR-T is a type of treatment in which a patients T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patients blood. Then the gene for a special receptor that binds to a certain protein on the patients cancer cells is [] Read more

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE